Bicara Therapeutics Inc. Common Stock (BCAX) quarterly cash flow statement — complete operating, investing & financing history
Bicara Therapeutics Inc. Common Stock (BCAX) cash flow statement — 4-year operating, investing & financing cash flows
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q1'23 |
|---|
| Cash from Operations | -44.21M | -37.51M | -23.89M | -29.25M | -25.59M | -28.11M | -30.03M | -17.22M | -12.91M | -14.59M | -8.04M | -13.53M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -72.72% | -33.45% | 20.46% | -69.81% | -98.28% | -92.68% | -273.72% | - | - | -7.81% | - | - |
| Net Income | -55.44M | -56.21M | -37.39M | -36.33M | -27.39M | -36.85M | -20.96M | -17.48M | -17.05M | -12.51M | -12.44M | -8.35M |
| Depreciation & Amortization | 44K | 44K | 43K | 24K | 19K | 19K | 15K | 15K | 13K | 13K | 14K | 1.5K |
| Stock-Based Compensation | 8.24M | 5.86M | 4.45M | 3.61M | 3.49M | 3.45M | 3.18M | 2.03M | 1.04M | 1.15M | 765K | 307.5K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -11.21M | 611K | 566K | 281K | 211K | 138K | -276K | 68K | 66K | 65K | 681K | -5.05M |
| Working Capital Changes | 14.16M | 12.19M | 8.44M | 3.16M | -1.93M | 5.13M | -11.99M | -1.86M | 3.02M | -3.3M | 2.94M | -440K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 4.96M | 10.37M | 7.92M | 3.78M | -2.38M | 1.16M | 4.28M | -1.68M | 0 | 0 | 0 | 0 |
| Cash from Investing | -184.99M | 100.94M | -82.33M | -236.12M | 0 | 0 | -40K | -8K | -19K | 58K | -436K | 0 |
| Capital Expenditures | -60K | -60K | -238K | -42K | 0 | 0 | -40K | -8K | -19K | -4K | -436K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62K | 0 | 0 |
| Cash from Financing | 2.33M | 163.34M | 31.23M | 436K | 135K | 460K | -975K | 334.13M | 734K | 137K | 194.7M | 18.95M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 2.33M | 163.34M | 31.23M | 436K | 135K | 460K | -1.05M | 334.13M | 0 | 0 | 194.7M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 77K | 0 | 734K | 137K | 0 | 18.95M |
| Net Change in Cash | -226.86M | 226.78M | -74.99M | -264.93M | -25.46M | -27.65M | -31.05M | 316.9M | -12.19M | -14.39M | 186.23M | 0 |
| Free Cash Flow | -44.27M | -37.57M | -24.12M | -29.29M | -25.59M | -28.11M | -30.07M | -17.23M | -12.93M | -14.59M | -8.47M | -13.53M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -72.95% | -33.67% | 19.78% | -69.97% | -97.99% | -92.63% | -254.96% | - | - | -7.84% | - | - |
| FCF per Share | -0.65 | -0.62 | -0.44 | -0.54 | -0.47 | -0.52 | -0.55 | -0.32 | -0.24 | -0.27 | -0.16 | -0.25 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.67x | 0.64x | 0.81x | 0.93x | 0.76x | 1.43x | 0.99x | 0.76x | 1.17x | 0.65x | 1.62x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 0 | 0 |